CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $3.85B, above the global median of $1.15B
- PositionOperating margin is 49%, higher than 95% of its Biotechnology peers (median -23.8%)
- Interpretations17 currently firing — 17
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.85BUSDvs all stocks (USD)
Trailing P/E
18.20xvs Biotechnology peers
Revenue (TTM)
596.96MUSDvs all stocks (USD)
Profit Margin
37.08%vs Biotechnology peers
Beta
0.7420xvs all stocks
52-Week Change
49.88%vs all stocks
Market Capitalization
3.85BUSDvs all stocks (USD)
Enterprise Value
3.10BUSDvs all stocks (USD)
Trailing P/E
18.20xvs Biotechnology peers
Forward P/E
9.05xvs Biotechnology peers
PEG Ratio
1.71xvs Biotechnology peers
Price to Sales (TTM)
6.46xvs Biotechnology peers
Price to Book (MRQ)
3.80xvs Biotechnology peers
Enterprise to Revenue
5.19xvs Biotechnology peers
Enterprise to EBITDA
10.14xvs Biotechnology peers
Gross Margin
90.31%vs Biotechnology peers
Profit Margin
37.08%vs Biotechnology peers
Operating Margin
49.02%vs Biotechnology peers
Return on Assets (TTM)
16.27%vs Biotechnology peers
Return on Equity (TTM)
24.50%vs Biotechnology peers
Revenue (TTM)
596.96MUSDvs all stocks (USD)
Revenue per Share (TTM)
4.87USDUpdated Jul 18, 2026Quarterly Revenue Growth
5.60%vs Biotechnology peers
Gross Profit (TTM)
501.66MUSDvs all stocks (USD)
EBITDA (TTM)
302.75MUSDvs all stocks (USD)
Net Income (TTM)
221.32MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
12.30%vs Biotechnology peers
Operating Cash Flow (TTM)
208.21MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
171.81MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
588.99MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
87.25MUSDFY2025 · Dec 31, 2025Gross Profit
501.74MUSDFY2025 · Dec 31, 2025Operating Income
257.78MUSDvs all stocks (USD)
Pre-tax Income
283.51MUSDFY2025 · Dec 31, 2025Income Tax Expense
69.19MUSDFY2025 · Dec 31, 2025Net Income
214.33MUSDFY2025 · Dec 31, 2025EBIT
257.78MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
294.68MUSDFY2025 · Dec 31, 2025Research & Development
12.71MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
193.75MUSDFY2025 · Dec 31, 2025EPS (Basic)
1.75USDFY2025 · Dec 31, 2025EPS (Diluted)
1.68USDFY2025 · Dec 31, 2025Basic Shares Outstanding
122.29MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
122.29MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
214.33MUSDFY2025 · Dec 31, 2025Operating Cash Flow
185.19MUSDFY2025 · Dec 31, 2025Free Cash Flow
185.13MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
709.17MUSDFY2025 · Dec 31, 2025Income Tax Paid
71.99MUSDFY2025 · Dec 31, 2025Interest Paid
466.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
214.33MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
37.87MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-6.85MUSDFY2025 · Dec 31, 2025Stock-based Compensation
24.78MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-55.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-61.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-5.39MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-18.49MUSDFY2025 · Dec 31, 2025Capital Expenditures
-58.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
0.00USDFY2025 · Dec 31, 2025Purchase of Investments
0.00USDFY2025 · Dec 31, 2025Net Investing Cash Flow
-58.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-25.30MUSDFY2025 · Dec 31, 2025Other Financing Charges
-6.36MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-31.66MUSDFY2025 · Dec 31, 2025Shares Outstanding
122.18MSharesUpdated Jul 18, 2026Float Shares
115.58MSharesUpdated Jul 18, 2026Shares Short
7.85MSharesUpdated Jul 18, 2026Short Ratio
4.11daysvs all stocks
Short % of Shares Outstanding
6.78%vs all stocks
% Held by Insiders
5.57%vs all stocks
% Held by Institutions
90.00%vs all stocks
Total Cash (MRQ)
755.86MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
6.18USDUpdated Jul 18, 2026Total Debt (MRQ)
2.68MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0027xvs Biotechnology peers
Current Ratio (MRQ)
7.10xvs Biotechnology peers
Book Value per Share (MRQ)
8.29USDUpdated Jul 18, 2026Total Assets
1.10BUSDvs all stocks (USD)
Total Current Assets
894.03MUSDFY2025 · Dec 31, 2025Total Liabilities
149.71MUSDFY2025 · Dec 31, 2025Total Non-current Assets
209.95MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.56MUSDFY2025 · Dec 31, 2025Total Current Liabilities
147.15MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
709.17MUSDFY2025 · Dec 31, 2025Accounts Receivable
126.48MUSDFY2025 · Dec 31, 2025Inventory
37.17MUSDFY2025 · Dec 31, 2025Accounts Payable
11.20MUSDFY2025 · Dec 31, 2025Short-term Debt
437.00KUSDFY2025 · Dec 31, 2025Other Current Liabilities
840.00KUSDFY2025 · Dec 31, 2025Long-term Debt
2.35MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
209.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
123.00KUSDFY2025 · Dec 31, 2025Retained Earnings
474.19MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
954.27MUSDvs all stocks (USD)
52-Week Low
19.05USDUpdated Jul 18, 202652-Week High
32.56USDUpdated Jul 18, 202652-Week Change
49.88%vs all stocks
Beta
0.7420xvs all stocks
50-Day MA
31.26USDUpdated Jul 18, 2026200-Day MA
25.41USDUpdated Jul 18, 2026Avg 10-Day Volume
3.01MSharesUpdated Jul 18, 2026Avg 30-Day Volume
2.29MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
1.73USDUpdated Jul 18, 2026Other Income / Expense
972.00KUSDFY2025 · Dec 31, 202517 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Three Asset-Base Ratios Elevated
It gets more sales from its assets than its industry does, and a lot of profit from them too.
Reads
Cash Backing With Revenue And Income Streaks
Revenue has risen in each of three years, profit in all three, and it holds more cash than debt.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion Levels
Its gross margin and its cash margin are high for its industry, and its operating margin is high outright.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Three Margin Ratios Elevated Across Gross, Operating, And Net Levels
Its gross and net margins are high for its industry, and its operating margin is high outright.
Reads
Multi-Year FCF With Growth And Margin
Three years of positive free cash flow and rising revenue, four of rising equity, and much of its sales turns into cash.
Reads
Three-Year Positive Free Cash Flow With Elevated ADX Asymmetry And 50w SMA Above 200w SMA
Three years of positive free cash flow, with the 50-week average above the 200-week.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Is this company growing?
Multi-Year Revenue, Profit, And Income Growth
Revenue has risen in each of three years, gross profit in each of four, and it has made a profit in all five.
Reads
Revenue Growth With Elevated Margin
Revenue up in each of five years, while its operating margin stays high.
Reads
How is this stock valued?
High Retained Earnings With Profitability And Equity
Profits kept in the business fund much of what it owns, after five straight profitable years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 49%, higher than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: 0.49Industry median: -0.24Industry P95: 0.38Peers compared: 197
Profit margin is 37.1%, higher than 95% of its Biotechnology peers (median -34%)Significant
Profit margin: 0.37Industry median: -0.34Industry P95: 0.37Peers compared: 197
Return on equity is 24.5%, higher than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: 0.24Industry median: -0.25Industry P95: 0.23Peers compared: 197
Financial Health
High earnings qualityNotable
Earnings Quality Score: 0.57
High structural barrier to entryNotable
Barrier to Entry: 0.68
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $3.85B, above the global median of $1.15BNotable
Market cap (USD): 3,854,925,752Global Median: 1,146,734,693.424
Revenue is $596.96M, above the global median of $520.53MNotable
Revenue (USD): 596,958,016Global Median: 520,528,949.311
Levered free cash flow is $171.81M, above the global median of $16.24MNotable
Levered free cash flow (USD): 171,809,872Global Median: 16,239,329.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Apeloa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Huahai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yuyue Medical Equipment & Supply Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Duality Biotherapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Xiamen Amoytop Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Enliven Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Livzon Pharmaceutical Group Inc.
Tier 1ProductionApproval-Gated PipelineRule
Dyne Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Beijing Tiantan Biological Products Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
NewAmsterdam Pharma Co. N.V.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
NVIDIA Corporation
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
Games Workshop Group PLC
15 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked Return on Capital ElevatedIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsThree Asset-Base Ratios ElevatedMulti-Year FCF With Growth And Margin
United States Lime & Minerals Inc.
14 interpretationsThree Margin Ratios Elevated Across Gross, Operating, And Cash-Conversion LevelsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesHigh Retained Earnings With Profitability And EquityCash Backing With Revenue And Income StreaksFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingMulti-Year Revenue, Profit, And Income GrowthRevenue Growth With Elevated MarginIndustry-Benchmarked ROA and Margin ElevatedThree Margin Ratios Elevated Across Gross, Operating, And Net LevelsMulti-Year FCF With Growth And MarginMulti-Year Debt Decrease With Cash Near Total Debt And Equity